Recifercept

BIOLOGICAL5 trials

Sponsors

Pfizer

Conditions

AchondroplasiaHealthy

Phase 1

Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept

CompletedNCT04543344

Start: 2020-09-17End: 2021-11-26Updated: 2022-01-10

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants

WithdrawnNCT05061277

Start: 2023-10-25End: 2024-06-16Updated: 2023-04-18

Phase 2

A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

TerminatedNCT04638153

PfizerAchondroplasia

Start: 2020-12-02End: 2023-03-27Updated: 2024-02-15

Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia

TerminatedNCT05116046

PfizerAchondroplasia

Start: 2021-12-24End: 2023-03-30Updated: 2024-02-08

Unknown Phase

A Study to Learn About Recifercept in Patients With Achondroplasia

CompletedNCT05659719

PfizerAchondroplasia

Start: 2022-10-19End: 2023-05-16Updated: 2024-09-20

Related Papers

Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial.

2023-10-0211 citations